Cingulate Inc. CING
are a biopharmaceutical company using our proprietary Precision Timed ReleaseTM ("PTRTM") drug delivery
platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With
an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder ("ADHD") and anxiety, we are identifying and
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $9.8M | $9.4M | $15.5M | $9.0M | $8.4M | $5.1M | — |
| SG&A | $10.2M | $6.2M | $7.3M | $8.5M | $12.3M | $2.0M | — |
| Operating income | -$19.9M | -$15.6M | -$22.8M | -$17.5M | -$20.7M | -$7.1M | — |
| Interest expense | $1.4M | $99.2K | $790.0K | $292.3K | — | — | — |
| Pre-tax income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M | -$7.2M | — |
| Net income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M | -$7.2M | — |
| EPS, basic | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 | — | — |
| EPS, diluted | -4.44 | -10.86 | -311.99 | -29.35 | -2.79 | — | — |
| Shares, diluted (wtd. avg.) | 5.1M | 1.5M | 75,435 | 602,340 | 7.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.0M | $12.2M | $52.4K | $5.4M | $16.5M | $1.2M | $418.5K |
| Short-term investments | — | — | — | — | $933 | $933 | — |
| Total current assets | $12.0M | $12.7M | $578.6K | $7.9M | $18.9M | $1.8M | — |
| Property, plant and equipment | $1.7M | $2.1M | $2.5M | $2.9M | $3.1M | $3.0M | — |
| Total assets | $15.1M | $14.9M | $3.5M | $11.4M | $22.9M | $5.8M | — |
| Accounts payable | $2.0M | $1.3M | $5.2M | $762.4K | $264.7K | $975.1K | — |
| Total current liabilities | $10.3M | $5.0M | $10.2M | $7.0M | $1.2M | $3.4M | — |
| Total liabilities | $12.6M | $7.4M | $10.4M | $7.5M | $2.0M | $4.5M | — |
| Retained earnings | -$132.4M | -$109.9M | -$92.9M | -$69.4M | -$51.7M | -$31.0M | — |
| Total equity | $2.5M | $7.5M | -$6.9M | $3.9M | $20.8M | $1.3M | $615.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.2M | -$18.5M | -$15.0M | -$15.9M | -$10.4M | -$6.8M | — |
| Depreciation and amortisation | $540.9K | $653.1K | $582.9K | $394.0K | $708.3K | $666.0K | — |
| Stock-based compensation | $1.5M | $995.5K | $812.7K | $800.8K | $43.8K | — | — |
| Capital expenditure | $162.1K | $211.8K | $224.1K | $153.4K | $814.7K | $402.1K | — |
| Investing cash flow | -$162.1K | -$211.8K | -$224.1K | -$152.7K | -$814.7K | -$384.2K | — |
| Financing cash flow | $16.1M | $30.8M | $10.0M | $4.9M | $26.5M | $8.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-010882.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$7.2M | -$20.7M | -$17.7M | -$23.5M | -$16.6M | -$22.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |